4Chenan T,ElHefnawy AM,Simonetti OP,et al.Rate of elitnisation of exceas CO2 in humans,Respir Physiol,1988,73:379.
5Kowalehuk JM,Heigenhuser GJF,Lindinger ML,et al.Factorsiafluencing bydrogen ion concentration in mualcs after intense exercise,J Appl Pyhaiol,1988,65:2080.
6Brown SE,Nagendran RC,McHugh JW,et al.Effectn of a large carbo-hydrata load on walking performance in chmoic air-flow obstrution.AM Rev Respir Dis,1985,132:960.
2[10]Compton CH, Gubb J, Nieman R, et al. Cilomilast, a selective phosphodiesterase-4 inhibitor for treatment of patients with chronic obstructive pulmonary disease: a randomised, dose-ranging study. Lancet,2001,358(9278):265～270
3[15]Di Lorenzo G, Morici G, Drago A,et al. Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group. Clin Ther,1998,20(6):1130～1148
4[16]Oren R, Beeri M, Hubert A, et al.Effect of theophylline on erythrocytosis in chronic obstructive pulmonary disease. Arch Intern Med,1997,157(13):1474～1478
5[17]Nakamura A, Kasamatsu N, Hashizume I, et al. Effects of hemoglobin on pulmonary arterial pressure and pulmonary vascular resistance in patients with chronic emphysema. Respiration, 2000,67(5):502～506
6[1]Miravitlles M,Mayordomo C, Artes M,et al.Treatment of chronic obstructive pulmonary disease and its exacerbations in general practice.Respir Med,1999 ,93(3):173～179
7[6]Tsukino M,Nishimura K,Ikeda A,et al.Effects of theophylline and ipratropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. Thorax,1998,53(4):269～273
8[7]Dorinsky PM, Reisner C, Ferguson GT,et al. The combination of ipratropium and albutreol optimizes pulmonary function reversibility testing in patients with COPD. Chest, 1999,115(4): 966～971
9[8]Villani F,De Maria P, Ronchi E, et al. Oral doxophylline in patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther,1997 ,35(3):107～111
